Detalhe da pesquisa
1.
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Clin Infect Dis
; 77(10): 1423-1431, 2023 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37340869
2.
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
N Engl J Med
; 382(12): 1124-1135, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130806
3.
Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
AIDS Behav
; 24(12): 3533-3544, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32447500
4.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Lancet
; 390(10101): 1499-1510, 2017 Sep 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-28750935
5.
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Lancet
; 382(9893): 700-8, 2013 Aug 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-23830355
6.
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
AIDS
; 35(9): 1333-1342, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33730748
7.
Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Lancet HIV
; 8(4): e185-e196, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33794181
8.
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
HIV Res Clin Pract
; 20(4-5): 111-122, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31533539
9.
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
AIDS Res Hum Retroviruses
; 34(4): 343-346, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29444582
10.